Lansoprazole for Subgroups of Functional Dyspepsia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pharmacotherapy for functional dyspepsia remains unsatisfactory. Previous randomized trials reported conflicting results on clinical effectiveness of proton pump inhibitor in patients with functional dyspepsia. This study aims to examine whether lansoprazole 15mg is more effective than placebo for functional dyspepsia in Taiwanese patients, and to investigate the association between subgroups of patients and therapeutic response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis

NCT00175045

Esophagitis Reflux

COMPLETED PHASE2

Lesogaberan in Chinese Patients With Refractory Reflux Symptoms

NCT02818309

Gastroesophageal Reflux Disease

UNKNOWN PHASE2

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00389948

Heartburn

COMPLETED PHASE3

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

NCT00390390

Heartburn

COMPLETED PHASE3

The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease

NCT01039558

Gastroesophageal Reflux Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective double-blind randomized placebo-controlled trial. A total of 450 dyspeptic adult patients, who are diagnosed with functional dyspepsia in accordance with Rome III criteria, are randomly allocated in a 1:1 proportion to receive either lansoprazole 15mg or placebo once daily for 8 weeks. Primary outcome is complete relief of dyspeptic symptoms. Secondary outcomes include significant symptomatic relief, improvement of dyspepsia severity, and health-related quality of life. We use a multiple logistic regression analysis to investigate whether dyspepsia subgroups are associated with different therapeutic responses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Functional Dyspepsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

lansoprazole

lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks

Group Type EXPERIMENTAL

Lansoprazole

Intervention Type DRUG

lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks

placebo

placebo once daily for eight weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

placebo once daily for eight weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lansoprazole

lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks

Intervention Type DRUG

placebo

placebo once daily for eight weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Takepron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Dyspeptic adult outpatients
* Characteristic dyspeptic symptoms according to Rome III criteria (bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning)
* Upper gastrointestinal endoscopy excluding structural diseases

Exclusion Criteria

* aged less than 20 years old,
* organic lesions such as peptic ulcer, tumor of any kind, stricture or structural deformity, erosive esophagitis, or vasculopathy on endoscopy
* typical and predominant reflux symptoms (heartburn or acid regurgitation)
* comorbidity with malignancy, diabetes mellitus, liver cirrhosis, renal failure, or porphyria
* history of intra-abdominal surgery
* concurrent use of aspirin, non-steroidal anti-inflammatory drug or proton pump inhibitor
* history of allergy or severe side effects to lansoprazole
* pregnant or lactating women.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No